ArticleStroke (Hoboken, N.J.)2026
Aspirin Use and the Risk of Symptomatic Hemorrhage in Patients With Cerebral Cavernous Malformations and Ischemic Cerebrovascular Disease.
Article in Stroke (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebral cavernous malformations (CCMs) are a common cause of spontaneous intracerebral hemorrhage (ICH). However, the association of aspirin with the hemorrhage risk of CCMs remains unclear.
methodsThis retrospective study consecutively enrolled patients with CCMs and asymptomatic or symptomatic ischemic cerebrovascular disease between March 2015 and July 2024. Baseline and follow-up information, including ICH presentation and aspirin use, were recorded. The primary outcome was a CCM-related hemorrhage event, defined as the onset of any new or worsened clinical symptoms caused by overt ICH, confirmed by radiological evidence. Independent factors of symptomatic hemorrhage were analyzed using Cox regression before and after 1:1 propensity score matching.
resultsAmong 259 patients with untreated CCMs, 129 (49.8%) patients took aspirin daily. Over a total follow-up time of 793.0 person-years, new clinical hemorrhage events occurred in 30 (11.6%) patients, including 27 (20.8%) in the nonaspirin group and 3 (2.3%) in the aspirin group. Multivariable Cox analysis revealed that CCM size, developmental venous anomaly, and ICH presentation were associated with a high risk of CCM hemorrhage, whereas aspirin use (hazard ratio, 0.13 [95% CI, 0.03-0.61];
conclusionsAspirin use is associated with a lower risk of symptomatic hemorrhage in patients with CCMs and ischemic cerebrovascular disease. Prospective studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.